Designing Effective Dashboards to Track KRIs in Clinical Trials

The Role of Dashboards in RBM

As Risk-Based Monitoring (RBM) becomes the norm in clinical trials, dashboards are increasingly used to visualize Key Risk Indicators (KRIs) for timely decision-making. Rather than sifting through spreadsheets or static reports, dashboards offer real-time insights with visual cues like colors, graphs, and alerts that enable quicker responses to emerging risks.

Modern dashboards aggregate data from systems such as CTMS, EDC, eTMF, and safety databases to present a holistic view of trial health. Regulators expect sponsors and CROs to use these tools as part of quality oversight and to demonstrate proactive monitoring during inspections.

Core Design Elements of a KRI Dashboard

An effective KRI dashboard is user-centric, actionable, and visually structured. Key elements include:

• Color-coded status indicators: Green (acceptable), Yellow (warning), Red (critical)
• Trend lines: Show change in KRI values over time
• Drill-down capability: Enables site-level investigation
• KPI benchmarks: Thresholds derived from protocol-specific parameters
• Filter and export options: By site, region, CRA, or KRI type

For example, a protocol deviation rate KRI might be represented as a gauge chart with red zones indicating breaches. Check out PharmaSOP for SOPs on defining KRI thresholds and dashboard escalation policies.

Sample KRI Dashboard Layout

Below is a hypothetical layout of a KRI dashboard for a multicenter clinical trial:

Site	SAE Reporting Lag	Protocol Deviations	Data Entry Lag	ICF Error Rate	Overall Status
Site 001	24h	2.5	2 days	4%
Site 002	18h	1.2	1 day	0.8%
Site 003	60h	3.8	4 days	2.2%

Each row in the dashboard highlights a trial site, enabling central monitors to prioritize follow-up. Traffic light visuals make it easier to digest information at a glance.

Integrating Dashboards with Source Systems

To be effective, KRI dashboards must pull data automatically from validated systems. This eliminates manual entry errors and ensures timeliness. The most common data integrations include:

• EDC (Electronic Data Capture): For data entry timestamps, queries, AE/SAE timing
• CTMS: Site visit dates, CRA reports, subject visit tracking
• eTMF: Consent forms, site documents, deviation logs
• Safety Databases: For real-time SAE reporting monitoring

Dashboards must be validated under GxP if they are used for decision-making. Tools like Tableau, Power BI, or RBM-specific platforms like Medidata Detect or CluePoints support compliance-ready visualization. See PharmaValidation for dashboard validation guidance.

Regulatory Expectations for KRI Dashboards

Regulators have acknowledged dashboard usage during audits and inspections. FDA BIMO inspections and EMA GCP inspectors may request:

• Evidence of real-time oversight using dashboards
• Defined escalation paths tied to dashboard alerts
• Audit trails showing updates, user access, and data flow
• SOPs covering visualization usage and interpretation

Documentation and training are critical. Just having a dashboard is not sufficient—it must be operational, monitored, and linked to CAPA workflows if thresholds are breached.

Best Practices in KRI Dashboard Implementation

• Limit visuals to 6–8 core KRIs to avoid clutter
• Use standard legends and colors across studies
• Establish site-specific thresholds for high-risk studies
• Refresh dashboards daily or weekly depending on trial phase
• Enable role-based access (e.g., CRA, QA, Central Monitor)

Train users not just to read dashboards, but to interpret trends and act. Integrating dashboards into weekly monitoring calls improves adoption and consistency.

Final Thoughts: Making Dashboards Work for You

KRIs provide data—but dashboards provide clarity. A well-designed dashboard is more than a visual tool; it’s an integral part of your trial oversight strategy. When used proactively, dashboards help you stay ahead of risks, improve subject safety, and ensure quality across all trial sites.

Further Reading

• FDA Guidance on Risk-Based Monitoring
• EMA Reflection Paper on Risk-Based Quality Management
• ICH E6(R2) Good Clinical Practice Guideline